source
- Takeda’s ADC arcotatug tavatecan shows survival benefit in phase 3 gastric cancer trialTakeda, together with Innovent Biologics, presented results from a late‑stage study of its next‑generation claudin‑18.2 antibody‑drug conjugate, arcotatug tavatecan (also known as IBI343 or TAK‑921…
- Lycia Therapeutics raises $317.5 million in IPO as Merck halts sac-TMT trialLycia Therapeutics, founded by Nobel laureate Carolyn Bertozzi, priced its initial public offering at about $317.5 million, bringing total proceeds to roughly $318 million. The offering marks the…